Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 532

    1.

    A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

    Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP.

    Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31.

    PMID:
    16737553
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

    Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

    Clin Cancer Res. 2005 May 1;11(9):3315-9.

    PMID:
    15867229
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N.

    N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10.

    PMID:
    15591335
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

    Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N.

    J Clin Oncol. 2006 Aug 10;24(23):3726-34. Epub 2006 May 23.

    PMID:
    16720680
    [PubMed - indexed for MEDLINE]
    5.

    Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.

    Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.

    Cancer. 2008 Feb 15;112(4):731-6.

    PMID:
    18076012
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

    Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

    J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. Epub 2009 Nov 28.

    PMID:
    19946706
    [PubMed - indexed for MEDLINE]
    7.

    A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.

    Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ.

    Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7.

    PMID:
    16609019
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.

    Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F.

    BMC Cancer. 2008 Nov 21;8:339.

    PMID:
    19025599
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.

    Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group.

    Cancer. 2010 Jul 1;116(13):3112-8.

    PMID:
    20564629
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

    Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

    Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

    PMID:
    18159035
    [PubMed - indexed for MEDLINE]
    11.

    Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.

    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.

    Cancer. 2008 Apr 1;112(7):1437-44.

    PMID:
    18286526
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

    Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

    Breast Cancer Res Treat. 2009 Jan;113(2):275-83. Epub 2008 Mar 4.

    PMID:
    18311582
    [PubMed - indexed for MEDLINE]
    13.

    Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

    Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R.

    J Clin Oncol. 2008 Nov 1;26(31):5036-42. Epub 2008 Aug 18.

    PMID:
    18711169
    [PubMed - indexed for MEDLINE]
    14.

    Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

    Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.

    PMID:
    18668363
    [PubMed - indexed for MEDLINE]
    15.

    ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.

    Stål O, Borg A, Fernö M, Källström AC, Malmström P, Nordenskjöld B; South Sweden Breast Cancer Group. Southeast Sweden Breast Cancer Group.

    Ann Oncol. 2000 Dec;11(12):1545-50.

    PMID:
    11205461
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.

    Khoshnoud MR, Fornander T, Johansson H, Rutqvist LE.

    Breast Cancer Res Treat. 2008 Jan;107(1):71-8. Epub 2007 Feb 15.

    PMID:
    18043896
    [PubMed - indexed for MEDLINE]
    17.

    Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Group.

    J Clin Oncol. 2005 Nov 1;23(31):7842-8.

    PMID:
    16258087
    [PubMed - indexed for MEDLINE]
    18.

    Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

    Lyman GH, Cosler LE, Kuderer NM, Hornberger J.

    Cancer. 2007 Mar 15;109(6):1011-8.

    PMID:
    17311307
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

    Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

    Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.

    PMID:
    17601725
    [PubMed - indexed for MEDLINE]
    20.

    Overview of resistance to systemic therapy in patients with breast cancer.

    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

    Adv Exp Med Biol. 2007;608:1-22. Review.

    PMID:
    17993229
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk